Elevated quetiapine serum concentrations in a patient treated concomitantly with doxepin, lorazepam, and pantoprazole.
Härtter
Sebastian
S
Connemann
Bernhard
B
Schönfeldt-Lecuona
Carlos
C
Sachse
Julia
J
Hiemke
Christoph
C
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004316:Doxepin / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004942:Esophagitis, Peptic / Q000097:blood / Q000188:drug therapy; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D009853:Omeprazole / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D013454:Sulfoxides / Q000009:adverse effects* / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D001562:Benzimidazoles; D003987:Dibenzothiazepines; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D004316:Doxepin; D000069348:Quetiapine Fumarate; D000077402:Pantoprazole; D009853:Omeprazole; D008140:Lorazepam